期刊文献+

临床药师对乙型肝炎患者抗病毒治疗药学宣教的效果分析 被引量:5

Analysis of the Effect of Pharmacy Education by Clinical Pharmacists on Antiviral Therapy for Type B Hepatitis Patients
原文传递
导出
摘要 目的:了解具有抗病毒治疗指征的慢性乙型肝炎病毒(HBV)感染肝病患者未接受抗病毒治疗的原因,并对抗病毒治疗药学宣教的效果进行评价。方法:随机选取住院和门诊具有抗病毒治疗指征的慢性HBV感染相关肝病患者,对未接受抗病毒治疗的患者进行原因分析。对住院患者开展抗病毒治疗的药学监护实践,并统计分析药学服务后的效果。结果:抗病毒治疗总体实施率为88.7%,门诊与住院患者差异无统计学意义;导致患者不接受抗病毒治疗的主要原因依次为经济因素(占28.6%)、担心耐药(占27.8%)、生育问题(占22.2%);临床药师对262名住院患者实施药学服务前后,各项统计指标差异均有统计学意义。结论:慢性乙型肝炎患者的抗病毒治疗实施率较高,经济因素、担心耐药、生育问题是目前制约患者实施抗病毒治疗的主要因素;临床药师在保证患者合理用药、确保药物疗效和提高服药依从性方面,发挥了重要作用。 OBJECTIVE: To understand the causes of chronic hepatitis B virus (HBV) infection patients with liver disease who did not receive antiviral therapy, and to evaluate the effect of pharmacy education on antiviral treatment. METHODS: The inpa- tients and outpatients with chronic HBV infection were randomly selected. The reasons for the patients who did not receive antiviral therapy were analyzed. The pharmaceutical care of antiviral therapy was developed for inpatients, and the effect of pharmaceutical care was analyzed statistically. RESULTS: The overall implementation rate of antiviral therapy was 88.7%; there was no statistical significance in outpatients and inpatients. The main reasons for patients not receiving antiviral treatment were economic factors (28.6%), fear of resistance (27.8%) and fertility problems (22.2%). Above indexes had statistical significance before and after clinical pharmacists provided pharmaceutical care for 262 inpatients. CONCLUSIONS: Antiviral therapy in patients with chronic HBV infection have high implementation rate relatively. Economic factors, worrying about resistance and fertility problems are the main factors of restricting the implementation of antiviral therapy. Clinical pharmacists play an important role in ensuring rational dru use and dru effect and imorovin medication comoliance.
出处 《中国药房》 CAS CSCD 2014年第6期559-560,共2页 China Pharmacy
关键词 乙型肝炎 抗病毒 药学监护 Type B hepatitis Antiviral therapy Pharmaceutical care
  • 相关文献

参考文献3

  • 1王宇明,程林.慢性乙型肝炎抗病毒优化治疗策略的新认识[J].中华肝脏病杂志,2012,20(2):82-85. 被引量:18
  • 2Lee M, Keeffe EB.Study of adherence comes to the treat- ment of chronic hepatitis B [J].J Hepatol, 2011,54 ( 1 ) : 6.
  • 3Zoulim F, Perrillo R.Hepatitis B: reflections on the current approach to antiviral therapy[J].J Hepatol, 2008,48 (sup- pl 1):S2.

二级参考文献23

  • 1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
  • 2Zoulim F,Perrillo R.Hepatitis B:reflections on the current approach to antiviral therapy.J Hepatol,2008,48 suppl 1:S2-19.
  • 3Lee M,Keeffe EB.Hepatitis B:modem end points of treatment and the specter of viral resistance.Gastroenterol Clin North Am,2011,40:495-505.
  • 4Farnik H,Lange CM,Hofmann WP,et al.Nucleos (t) ide analogue treatment reducesapoptotic activity in patients with chronic hepatitis B.J Clin Virol,2011,52:204-209.
  • 5Lai CL,Gane E,Liaw YF,et al.Telbivudine versus lamivudine in patients with chronic hepatitis B.N Engl J Med,2007,357:2576-2588.
  • 6Hou J,Yin YK,Xu D,et al.Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B:results at 1 year of a randomized,double-blind trial.Hepatology,2008,47:447-454.
  • 7Yuen MF,Lai CL.Telbivudine for chronic hepatitis B:the GLOBE trial.Future Virol,2008,3:317-323.
  • 8Liaw YF.On-treatment outcome prediction and adjustment during chronic hepatitis B therapy:now and future.Antivir Ther,2009,14:13-22.
  • 9Liaw YF,Gane E,Leung N,et al.2-Year GLOBE trial results:telbivudine Is superior to lamivudine in patients with chronic hepatitis B.Gastroenterology,2009,136:486-495.
  • 10Yuen MF,Fung J,Seto WK,et al.Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.Antivir Ther,2009,14:679-685.

共引文献17

同被引文献21

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部